TVM Capital Life Science and Yonjin Ventures co-led the funding round. Existing shareholders SV Health Investors, Ascension Ventures, First Analysis, Blue Heron and Intersouth Partners also participated. In connection with the financing, Dr. Luc Marengere of TVM and Dr. Deng Mao of Yonjin Ventures join CSA Medical’s board of directors.
The Boston-based company expects to use funds to progress through the FDA premarket approval efforts for its RejuvenAir system. Funds could also propel the commercialization strategy for a successful U.S. launch post-approval.
RejuvenAir, a proprietary interventional liquid nitrogen spray cryotherapy system, utilizes software-driven dosimetry and a specialty catheter. The technology enables the delivery of cryogen spray inside the airways to flash freeze and destroy damaged cells. The company designed it to allow for a rejuvenative pattern of healing.
CSA Medical aims to bring RejuvenAir to the market for the treatment of the underlying cause of chronic bronchitis: the overproduction of mucus and damaged cilia within the airways. The system targets and destroys the damaged cells without creating scar tissue. Then, the body can begin the rapid regrowth of new, healthy, normal functioning cells in the lung.
“We’re excited to bring new partners on board as we approach the next significant milestone of submitting the RejuvenAir system for regulatory approval,” said Wendelin Maners, CSA Medical CEO. “This new investment further validates the enormous market potential for the RejuvenAir therapeutic platform in this under-served patient population.” The RejuvenAir system is a medical device therapy aimed at treating the underlying cause of the chronic bronchitis, something no drug or device on the market does today.
